Related Experiment Videos
Pharmacokinetics of pirprofen in children with juvenile chronic arthritis
Insights
Pirprofen pharmacokinetics in children with juvenile chronic arthritis (JCA) were similar to adults, with no accumulation after repeated doses. The drug persisted longer in synovial fluid than plasma, similar to findings in rheumatic adults.
Area of Science:
- Pharmacology
- Pediatrics
- Rheumatology
Background:
- Juvenile chronic arthritis (JCA) is a significant pediatric condition requiring effective treatment.
- Understanding drug pharmacokinetics in pediatric populations is crucial for safe and effective therapeutic strategies.
- Pirprofen is a non-steroidal anti-inflammatory drug (NSAID) used for inflammatory conditions.
Purpose of the Study:
- To evaluate the pharmacokinetics of pirprofen in children with JCA.
- To compare pirprofen's pharmacokinetic profile in pediatric patients to healthy volunteers and elderly arthritic adults.
- To assess the safety and potential for drug accumulation with repeated pirprofen administration in children.
Main Methods:
- Single and repeated doses of pirprofen (100 or 200 mg) were administered to children with and without JCA.
- Pharmacokinetic parameters were analyzed and compared across different age groups and conditions.
- Regular clinical examinations and laboratory tests were conducted to monitor for adverse effects.
Main Results:
- Pirprofen pharmacokinetics were comparable between children and adults when adjusted for dose and body weight.
- No evidence of drug accumulation was observed following repeated pirprofen administration.
- Pirprofen exhibited prolonged retention in synovial fluid compared to plasma, consistent with observations in adult rheumatic patients.
Conclusions:
- Pirprofen demonstrates predictable pharmacokinetics in children with JCA, similar to adult populations.
- The drug appears safe for repeated administration in children without significant accumulation.
- The sustained presence of pirprofen in synovial fluid suggests potential for sustained anti-inflammatory effects in affected joints.
Abstract:
Pirprofen (100 or 200 mg; Rengasil) was administered to experimental groups of children (children with juvenile chronic arthritis, JCA) and to a control group of children (children without JCA) as a single dose or as repeated doses. The pharmacokinetics of pirprofen in these children were compared to the pharmacokinetic parameter values obtained in healthy volunteers and in elderly arthritic adults receiving 400 mg of pirprofen. The children were examined regularly and laboratory values were determined in order to detect possible side effects. The results demonstrated that the pharmacokinetics of pirprofen were similar for children and adults when taking into account the dose and the body weight. There was no drug accumulation after repeated administration of pirprofen. As already observed in rheumatic adults, pirprofen remains in synovial fluid longer than in plasma.